Natera(NTRA)携手Diakonos Oncology开发用于治疗难治性黑色素瘤的Signatera™

金吾财讯18:35

金吾财讯 | 全球无细胞DNA与精准医疗领域的领头羊Natera(NTRA)宣布，已与临床阶段生物技术公司Diakonos Oncology Corp.达成一项全新的全球战略合作。双方将联合利用Natera独家的Signatera分子检测技术，共同评估一款针对难治性黑色素瘤的创新树突状细胞疗法。根据合作协议，Natera将利用其核心的Signatera液体活检平台，对Diakonos正在进行的DOC-RM I/II期临床试验进行深度支持。该试验于今年5月刚刚启动，旨在对入组的难治性黑色素瘤患者在治疗期间及治疗后的多个时间点，进行长期的循环肿瘤DNA微小残留病灶纵向监测。值得关注的是，Diakonos本次临床所评估的个性化免疫疗法DOC1021(dubodencel)，此前已荣获美国食品药品监督管理局(FDA)授予的“快速通道资格认定”。据悉，难治性黑色素瘤是目前肿瘤学领域公认的“硬骨头”。尽管近年来免疫疗法彻底颠覆了晚期黑色素瘤的治疗格局，但仍有大量患者对治疗无反应或最终产生耐药性。此外，接受免疫治疗的患者在传统影像学(如CT、MRI)检查中往往存在疗效滞后的挑战。而通过Signatera对ctDNA进行连续监测，能比传统影像学更早地捕捉到分子层面的敏感反应与疾病动态。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2639621297?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png","is_english":false,"pubTime":"2026-05-29 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639621297","market":"other","top_or_hot":-1,"title":"Natera(NTRA)携手Diakonos Oncology开发用于治疗难治性黑色素瘤的Signatera™","media":"金吾财讯","content":"<html><body><p>金吾财讯 | 全球无细胞DNA与精准医疗领域的领头羊Natera(NTRA)宣布，已与临床阶段生物技术公司Diakonos Oncology Corp.达成一项全新的全球战略合作。双方将联合利用Natera独家的Signatera分子检测技术，共同评估一款针对难治性黑色素瘤的创新树突状细胞疗法。根据合作协议，Natera将利用其核心的Signatera液体活检平台，对Diakonos正在进行的DOC-RM I/II期临床试验进行深度支持。该试验于今年5月刚刚启动，旨在对入组的难治性黑色素瘤患者在治疗期间及治疗后的多个时间点，进行长期的循环肿瘤DNA微小残留病灶纵向监测。值得关注的是，Diakonos本次临床所评估的个性化免疫疗法DOC1021(dubodencel)，此前已荣获<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品监督管理局(FDA)授予的“快速通道资格认定”。据悉，难治性黑色素瘤是目前肿瘤学领域公认的“硬骨头”。尽管近年来免疫疗法彻底颠覆了晚期黑色素瘤的治疗格局，但仍有大量患者对治疗无反应或最终产生耐药性。此外，接受免疫治疗的患者在传统影像学(如CT、MRI)检查中往往存在疗效滞后的挑战。而通过Signatera对ctDNA进行连续监测，能比传统影像学更早地捕捉到分子层面的敏感反应与疾病动态。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera(NTRA)携手Diakonos Oncology开发用于治疗难治性黑色素瘤的Signatera™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera(NTRA)携手Diakonos Oncology开发用于治疗难治性黑色素瘤的Signatera™\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-29 18:35 北京时间&nbsp;&nbsp;&nbsp;<a href=300976><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 全球无细胞DNA与精准医疗领域的领头羊Natera(NTRA)宣布，已与临床阶段生物技术公司Diakonos Oncology Corp.达成一项全新的全球战略合作。双方将联合利用Natera独家的Signatera分子检测技术，共同评估一款针对难治性黑色素瘤的创新树突状细胞疗法。根据合作协议，Natera将利用其核心的Signatera液体活检平台，对Diakonos正在进行的...</p>\n\n<a href=\"300976\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1988902786.USD","symbol_name":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","start_time":0,"source_url":"300976","article_id":"2639621297","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639621297","pubTimestamp":1780050915,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"双方将联合利用Natera独家的Signatera分子检测技术，共同评估一款针对难治性黑色素瘤的创新树突状细胞疗法。根据合作协议，Natera将利用其核心的Signatera液体活检平台，对Diakonos正在进行的DOC-RM I/II期临床试验进行深度支持。据悉，难治性黑色素瘤是目前肿瘤学领域公认的“硬骨头”。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","NTRA":"Natera, Inc.","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","BK4139":"生物科技","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC"},"translate_title":"Natera (NTRA) Joins Diakonos Oncology to Develop Signatera for Treatment of Refractory Melanoma ™","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1.5},"content_text":"金吾财讯 | 全球无细胞DNA与精准医疗领域的领头羊Natera(NTRA)宣布，已与临床阶段生物技术公司Diakonos Oncology Corp.达成一项全新的全球战略合作。双方将联合利用Natera独家的Signatera分子检测技术，共同评估一款针对难治性黑色素瘤的创新树突状细胞疗法。根据合作协议，Natera将利用其核心的Signatera液体活检平台，对Diakonos正在进行的DOC-RM I/II期临床试验进行深度支持。该试验于今年5月刚刚启动，旨在对入组的难治性黑色素瘤患者在治疗期间及治疗后的多个时间点，进行长期的循环肿瘤DNA微小残留病灶纵向监测。值得关注的是，Diakonos本次临床所评估的个性化免疫疗法DOC1021(dubodencel)，此前已荣获美国食品药品监督管理局(FDA)授予的“快速通道资格认定”。据悉，难治性黑色素瘤是目前肿瘤学领域公认的“硬骨头”。尽管近年来免疫疗法彻底颠覆了晚期黑色素瘤的治疗格局，但仍有大量患者对治疗无反应或最终产生耐药性。此外，接受免疫治疗的患者在传统影像学(如CT、MRI)检查中往往存在疗效滞后的挑战。而通过Signatera对ctDNA进行连续监测，能比传统影像学更早地捕捉到分子层面的敏感反应与疾病动态。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2639621297","isCrawlerRequest":true}